INNOVUS PHARMACEUTICALS, INC. - FORM 10-K - EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - March 30, 2016

Attached files

file filename
EX-14.1 - CODE OF ETHICS - INNOVUS PHARMACEUTICALS, INC.ex_141.htm
10-K - ANNUAL REPORT - INNOVUS PHARMACEUTICALS, INC.innv_dec312015.htm
EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - INNOVUS PHARMACEUTICALS, INC.ex_211.htm
EX-32.1 - CERTIFICATION - INNOVUS PHARMACEUTICALS, INC.ex_321.htm
EX-31.2 - CERTIFICATION - INNOVUS PHARMACEUTICALS, INC.ex_312.htm
EX-23.2 - CERTIFICATION - INNOVUS PHARMACEUTICALS, INC.ex_232.htm
EX-31.1 - CERTIFICATION - INNOVUS PHARMACEUTICALS, INC.ex_311.htm
Exhibit 23.1
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
We consent to the incorporation by reference in the Registration Statement of Innovus Pharmaceuticals, Inc. (the “Company”) on Form S-8 (No. 333-186725-13620840), pertaining to the Company’s Incentive Stock Option Plan, Nonstatutory Stock Option Agreement, and the Company’s Equity Incentive Plan, and the Registration Statement of Innovus Pharmaceuticals, Inc. on Form S-8 ( No. 333-201352), pertaining to the Company’s registration of shares of the Company’s 2014 Equity Incentive Plan of our report dated March 31, 2015, on our audit of the consolidated financial statements as of December 31, 2014 and for the year ended December 31, 2014, which report is included in the Annual Report on Form 10-K for the year ended December 31,2015, filed on March 30, 2016. Our report includes an emphasis-of-matter paragraph highlighting the line of credit provided by the President and Chief Executive Officer of the Company, and deferral of the payment of his salary.

 
/S/ EISNER AMPER LLP
 
 
Iselin, New Jersey
 
 
March 30, 2016

INNOVUS PHARMACEUTICALS, INC. Reports